Project Grant R21EY038741
- The National Institute of Neurological Disorders and Stroke (part of the National Institutes of Health) awarded $361,125 to the University of California, Berkeley on September 1, 2026, under the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative (CFDA 93.372) as a project grant. The award funds a targeted planning project to establish a functional connectomics paradigm combining ultra-fast two-photon voltage imaging (2P-FACED) with two-photon optogenetic...
- The National Institute of Neurological Disorders and Stroke awarded the University of New England $319,500 on September 1, 2026, under the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative to establish the feasibility of applying CAMPARI3, a validated neuroscience tool that enables permanent labeling of activated neurons through green-to-red photoconversion, to corneal primary afferent neurons and to integrate the tool into broader neuroscience research at UNE. Aim...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded Yale University $272,970 under the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative on September 30, 2025. The award funds research on neural circuits regulating arousal and behavioral responses to visual threats. The project employs a virtual visual cliff task in mice to study the relationship between neuromodulators (norepinephrine and acetylcholine), attention, arousal, sensory...
- The National Institute of Neurological Disorders and Stroke awarded The Salk Institute for Biological Studies $150,104 on February 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to develop methods for growing brain organoids with improved structural complexity, cellular diversity, and long-term viability. The project, titled "3D Printing Hydrogel Vasculature and Bioactive Cues Within Brain Organoids," addresses...
- The National Institutes of Health (NIH) awarded a $1,385,000 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to the Allen Institute, a non-profit research organization, to develop novel techniques for measuring the input-output operations of individual neurons in the mouse cortex. The project aims to overcome challenges in understanding how neurons in the mammalian brain transform their synaptic inputs into outputs, which is critical for designing effective brain-machine...
- The National Institute of Neurological Disorders and Stroke awarded Massachusetts Institute of Technology $651,069 on May 2, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to develop spatially multiplexed imaging techniques for visualizing complex signaling networks in neurons and brain cells. The research advances a method called Signaling Reporter Islands (SIRIs) that enables simultaneous imaging of multiple cellular signals...
- The National Institute of Neurological Disorders and Stroke awarded the University of Illinois $599,169 on September 1, 2026, under the 21st Century Cures Act — Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, CFDA 93.372, to develop and validate contrast-free super-resolution ultrasound imaging techniques for functional imaging of neural circuits in the spinal cord. The research demonstrates phase subtraction imaging (PSI) and null subtraction imaging (NSI) as...
- The National Institute of Neurological Disorders and Stroke awarded Vanderbilt University $557,161 on July 10, 2026, under the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative (CFDA 93.372) to develop a novel bioluminescence resonance energy transfer (BRET) system for optimizing and imaging in vivo recording of neural activity in freely behaving animals. The project runs through June 30, 2029, with performance in Nashville, Tennessee. The award supports...
- The National Institute of Neurological Disorders and Stroke awarded Brigham Young University $550,159 on June 2, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate the role of MAB-5, a Hox transcription factor, in establishing and maintaining neuronal identity and connectivity. The research uses C. elegans Q neuroblasts as a model system to elucidate mechanisms of neuronal cell fate generation and maintenance. The...
- The National Institute of Neurological Disorders and Stroke (NINDS), part of the Department of Health and Human Services National Institutes of Health, awarded $153,560 to the Broad Institute, Inc. (doing business as Broad Institute of MIT and Harvard) on December 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds research examining how excitatory neurons regulate interneuron fate, position, and survival during...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded the University of Utah $616,000 on August 1, 2026, under the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative (Assistance Listing 93.372) to develop a high-throughput computational pipeline for rapid design of photocaged neuropeptides. The project addresses the NIH BRAIN Initiative goal to enable precise modulation of neural circuit components by creating a generalizable, open-source machine learning-based computational pipeline for rational design of photocaged neuropeptides that can activate specific neuropeptide-GPCR signaling pathways with light. Current optogenetic approaches simultaneously activate multiple neurotransmitters, obscuring neuropeptide-specific roles; photocaged neuropeptides overcome this limitation but remain challenging and resource-intensive to develop. The pipeline integrates solvent-accessibility mapping, receptor docking, and molecular dynamics simulations, leveraging experimentally resolved protein structures and AI-predicted AlphaFold2 models. The project focuses on 40 neuropeptide-GPCR pairs with experimentally solved structures and known roles in neurological diseases including autism spectrum disorders, postpartum depression, chronic pain, and metabolic diseases. Aim 1 generates computational models predicting optimal photocaging residues that prevent GPCR binding in darkness but restore ligand activity after targeted photolysis. Aim 2 experimentally validates predictions and creates a library of analogs; the top three analogs per neuropeptide are synthesized via solid-phase chemistry and screened in high-throughput GPCR assays to ensure minimal dark-state activity. Work is performed in Salt Lake City, Utah, with a period of performance from August 1, 2026, through July 31, 2029.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $616.0k | 7/20/26 |